The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs
Open accessAbstract
for an error in the Table .An incorrect indication was given for the drug ibrutinib; the correct indication is mantle cell lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leukemia, E. I. C. M. (2013) · Blood · doi:10.1182/blood-2013-03-490003 · Cited by 592
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Bach, P. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmhpr0807774 · Cited by 390
Cancer Drugs in the United States: Justum Pretium—The Just Price
Kantarjian, H. M., Fojo, T., Mathisen, M., & Zwelling, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1845 · Cited by 284
Cited by
Carrera, P. M., Kantarjian, H. M., & Blinder, V. S. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21443 · Cited by 876
Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies
Lentz, R., Benson, A. B., & Kircher, S. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25374 · Cited by 336
Aguiar, P. N., Haaland, B., Park, W., San Tan, P., del Giglio, A., & de Lima Lopes, G. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1395 · Cited by 124
Garrison, L. P., Jiao, B., & Dabbous, O. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.5.674 · Cited by 41
van Ewijk, R., Cleirec, M., Herold, N., le Deley, M.-C., van Eijkelenburg, N., Boudou-Rouquette, P., Risbourg, S., Strauss, S. J., Palmerini, E., Boye, K., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102625 · Cited by 19
Metadata
- Authors
- Mailankody, S., & Prasad, V.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2015-07-01
- Volume
- 1
- Issue
- 4
- Pages
- 539
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2060918723
- Cited by
- 300
- References
- 3
- FWCI
- 98.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. https://app.cochat.ai/papers/10.1001/jamaoncol.2015.0373
- The paper
- Mailankody, S., & Prasad, V. (2015). Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2015.0373
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.